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Two decades have passed since the first attempts were made to establish
systematic ethical review of human research in the Baltic States. Legally
and institutionally much has changed. In this paper we provide an historical
and structural overview of ethical review of human research and identify
some problems related to the role of ethical review in establishing quality
research environment in these countries. Problems connected to (a) public
availability of information, (b) management of conflicts of interest, (c) REC
composition and motivation of REC members, and (d) differing levels of
stringency of ethical review for different types of studies, are identified.
Recommendations are made to strengthen cooperation among the Baltic
RECs.
INTRODUCTION
In the Baltic States of Estonia, Latvia and Lithuania, as
in most countries of Central and Eastern Europe, system-
atic ethical review of biomedical research started in the
late 1980s. Two decades have passed, but information on
the day-to-day functioning of Research Ethics Commit-
tees (RECs) is still rather scarce and sporadic.1 In this
paper we attempt to close this information gap.
Our goal is twofold: (1) to present a general overview
of ethical review of human research in the Baltic States
and (2) to identify some of the problems related to the
role of ethical review in establishing a high quality
research environment. We believe that this overview may
provide some important insights into the processes of
ethical review and the protection of research participants
not only in the Baltic States but also in other transition
societies.
1 One of the first descriptions of RECs in Baltic States can be found in
J. Glasa, ed. 2000. Ethics Committees in Central and Eastern Europe.
Strasbourg: Council of Europe. However, recently there have been
some Europe-wide initiatives to collect information on ethical review of
human research that also covered the Baltic States. One important
source is the PRIVIREAL project, started in 2002. However, the infor-
mation provided by the project’s website (Privireal. 2005. Research
Ethics Committees – Countries. Sheffield, UK: Privireal. Available at:
http://www.privireal.org/content/rec/countries.php [Accessed 31 Mar
2010].) is in some respects already outdated. Results were published as
D. Beyleveld, D. Townend & J. Wright, eds. 2005. Research Ethics
Committees, Data Protection and Medical Research in European Coun-
tries. Hants: Ashgate. Another initiative is the European Forum for
Good Clinical Practice (EFGCP) ongoing survey of ethical review pro-
cedures and practices related to clinical drug trials. Even though infor-
mation provided by this survey is very recent (report was published in
2007 (EFGCP Ethics Working Party on the Structure and Function of
Research Ethics Committees in the European Union. The Procedure for
the Ethical Review of Protocols for Clinical Research Projects in the
European Union. Int J Pharm Med 2007; 21: 1–113.); updates on the
website are correct as of 2009 (EFGCP. 2009. Update of the Report, as
of 2009. Brussels: EFGCP. Available at: http://www.efgcp.be/
html.asp?what=efgcpreport.htm&L1=5&L2=1 [Accessed 31 Mar
2010].)) and comprehensive, it covers only a limited area of human
research because drug-unrelated clinical trials as well as other types of
biomedical research are not covered by the EU Clinical Trials Directive
(European Commission, Directive 2001/20/EC of 4 April 2001, of the
European Parliament and of the Council on the approximation of the
laws, Regulations and administrative provisions of the Member States
relating to implementation of good clinical practice in the conduct of
clinical trials on medicinal products for human use. OJ L 121,
1.05.2001, p. 34.) that the EFGCP activities are based on.
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LT-03101, Lithuania. Email: vilius.dranseika@fsf.vu.lt
Conflict of interest statement: No conflicts declared
Developing World Bioethics ISSN 1471-8731 (print); 1471-8847 (online) doi:10.1111/j.1471-8847.2010.00288.x
Volume 11 Number 1 2011 pp 48–54
bioethics
developing world
© 2010 Blackwell Publishing Ltd., 9600 Garsington Road, Oxford OX4 2DQ, UK and 350 Main Street, Malden, MA 02148, USA.
HISTORICAL AND STRUCTURAL
OVERVIEW
The emergence of ethical review of human research in the
Baltics, which began in late 1980s, can be traced back to
certain individuals who were knowledgeable about the
workings of ethical review in the West and who were
eagerly anticipating the first chance to join international
research.2 However, even though the Baltic States share
many socio-economic characteristics, all three have
developed rather different institutional models of ethical
review, despite their common motivation to facilitate
local researcher involvement in international research.
In Estonia, ad hoc committees for clinical trials were
created as early as 1989.3 The first permanent RECs were
established in 1990 by the University of Tartu and in 1992
by the Institute of Experimental and Clinical Medicine
(now National Institute for Health Development) in
Tallinn. These two RECs, affiliated with and dependent
upon mother institutions, also perform functions of regio-
nal RECs since they also review research proposals from
outside their own institutions. A national bioethics board,
the Estonian Council on Bioethics, was established in
1998. One of its tasks is to coordinate activities of regional
RECs. A special REC to review research conducted within
the Estonian Genome Project was established in 2001, but
its functions were later passed to the Ethics Review Com-
mittee on Human Research of the University of Tartu. In
2008, a special kind of REC, reviewing only matters
related to research with medical data from Estonian
e-health databases, was established. It is called the Ethics
Committee of the Health Information System.
The emergence of the Lithuanian ethical review system
was similar to that of Estonia. Two RECs were created in
the late 1980s as a consequence of local research institu-
tion initiative, and not as a realization of some national
policy. In 1994, the Law on the Health System4 was
adopted, thus setting the conditions for the official estab-
lishment of the national REC, the Lithuanian Medical
Ethics Committee (now Lithuanian Bioethics Commit-
tee) a year later. The Committee functions as a national
bioethics council and also has a subcommittee for ethical
review of biomedical research. In 2001, the Law on Ethics
of Biomedical Research5 introduced a two-tier system
with regional RECs. The Kaunas Regional Biomedical
Research Ethics Committee was thus established at
Kaunas University of Medicine in 2001. The second
regional REC was established at Vilnius University in
2008.
Latvia was the last of the Baltic States to start this
process. The first committee was founded at the Latvian
Institute of Cardiology in 1992 and was then called the
Ethics Committee of Clinical and Experimental
Research. The second REC was created by Riga Stra-
dins University in 1996, prior to any legal provisions
being enacted. In 1997, the Parliament adopted the
Medical Treatment Law6 creating a legal platform for
establishing medical ethics committees. In 1998, the
Statutes of Central Medical Ethics Committee7 were
approved.
The situation in Latvia is more complex than in the
other two countries. There are several kinds of RECs
with different jurisdictions and scopes of operation.
There is a national body, the Central Medical Ethics
Committee, and there are other RECs of two kinds: insti-
tutional ones and those which are sometimes referred to
as ‘regional’.8 However, these so-called ‘regional’ com-
mittees are not assigned to any particular region, all are
located in Riga, Latvia’s capital, and the law does not
require that applications for ethical review be submitted
according to region of origin. It would be more appro-
priate, therefore, to distinguish between RECs with a
narrow scope of review and RECs with a wide scope of
review. Three committees review only clinical drug trials,
one reviews drug trials and other types of human bio-
medical research, while four review all types of biomedi-
cal research, except clinical drug trials.
2 As is indicated by Lithuanian bioethicists, ‘[t]he process of develop-
ment of ethical review in Lithuania (and probably many other Central
and Eastern European countries) [. . .] was strongly facilitated by
foreign pharmaceutical companies.’ A. Cekanauskaite, E. Gefenas.
2005. Research Ethics Committees in Lithuania. In Beyleveld et al. eds.
op .cit. note 1: 140–147, p. 141. Similar views were expressed by Esto-
nian and Latvian experts as well. In the questionnaire received from one
of the Estonian RECs, it was indicated that the motive for the estab-
lishment was to embrace ‘new possibilities to take part in international
medical research. [. . .] The international requirements demanded inde-
pendent body for the overview of research projects.’ One of the Latvian
RECs also reported that the main motive was ‘the necessity to review
the research involving human participants, as well as rapid development
of drugs clinical research’.
3 T. Veidebaum. 2005. Research Ethics in Estonia. In Beyleveld et al.
eds., op. cit. note 1, pp. 41–43: 41.
4 Seimas of the Republic of Lithuania. 1995. Republic of Lithuania
Law on the Health System. Parliamentary Record, 12.01.1995, No.
12. Available at: http://www3.lrs.lt/pls/inter3/dokpaieska.showdoc_
e?p_id=23358 [Accessed 31 Mar 2010].
5 Seimas of the Republic of Lithuania. 2000. Republic of Lithuania Law
on Ethics of Biomedical Research. Available at: http://www3.lrs.lt/pls/
inter3/dokpaieska.showdoc_e?p_id=148740 [Accessed 31 Mar 2010].
6 Latvijas Republikas Saeima (Saeima of the Republic of Latvia). 1998.
Ārstniecı̄bas likums (Medical Treatment Law). Latvijas vēstnesis,
01.07.1997, Nr. 167. Available at: http://www.likumi.lv/doc.php?id=
44108 [Accessed 31 Mar 2010].
7 Latvijas Republikas Ministru kabinets (Cabinet of Ministers of the
Republic of Latvia). 1998. Centrālās medicı̄nas ētikas komitejas noli-
kums (Statutes of Central Medical Ethics Committee). Latvijas vēstne-
sis, 15.01.1998, Nr. 10. Available at: http://www.likumi.lv/doc.php?id=
46597 [Accessed 31 Mar 2010].
8 Eg. Privireal. 2005. Latvia – RECs and Medical Research. Sheffield,
UK: Privireal. Available at: http://www.privireal.org/content/rec/latvia.
php [Accessed 31 Mar 2010].
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In all three Baltic States, ethical review of human
research developed in bottom-up fashion. Initially RECs
were established in particular university hospitals or
medical faculties and only then were legal regulations put
in place. Consequently the institutional structure of
ethical review was reshaped by legal developments.
Currently all three systems of ethical review can be seen
as structures that include a national body and local or
regional committees established at various institutions
that engage in biomedical research. It is only in Lithuania
and Estonia where such local or regional committees are
assigned geographically defined jurisdictions although
some Latvian committees could be regarded as ‘regional
committees’ in that they review research proposals from
outside their founding institution even though there is no
defined geographic region.
The relationship between national and local or
regional RECs differs a lot across the Baltic States. For
example, Estonian RECs simply provide to the national
body annual reports about main facts and trends of their
operation. The RECs themselves have taken the initia-
tive. While in Lithuania, the division of responsibilities
and accountability between national and local bodies is
clearly defined in different normative documents.
All three national bodies (the Estonian Council on
Bioethics, the Latvian Central Medical Ethics Committee
and the Lithuanian Bioethics Committee) are state insti-
tutions. For example, the Lithuanian Bioethics Commit-
tee is an institution subordinate to the Ministry of
Health. However, national bodies differ in their func-
tions. For example, it is only the Lithuanian committee
that supervises the rest of the committees and reviews
their decisions upon appeal. The Lithuanian and Latvian
committees differ from their Estonian counterpart in that
they review research protocols. Before the introduction of
the two-tiered system, the Lithuanian committee was the
sole reviewer in the country. It is still the only body that
issues decisions on clinical drug trials and on biomedical
research studies that take place in more than one region.
The Latvian committee reviews: (a) research proposals
that are related to the National Genome Project and (b)
non-drug trials. The Estonian Council on Bioethics does
not review research.
In all three countries approvals of clinical trials of
medicinal products cannot be granted by RECs alone.
Each country has a State Agency of Medicines (called
State Medicines Control Agency in Lithuania) that also
participates in approval process. REC approval is a nec-
essary but not sufficient condition of issuing an approval
for a trial of this type. This is a direct outcome of the
adoption of the Directive 2001/20/EC.9
REC workload, summarized in Table 1, lists the num-
ber of approvals by country (the figures exclude student
research).
Figures 1–3 depict the organizational structure of
ethical review in the Baltic States. Solid lines show which
institutions issue approvals (or recommendations to issue
approvals) for particular types of research. Punctuated
lines show accountability of institutions. Dashed lines (in
Lithuanian figure only) show recommendations to other
committee.
ETHICAL REVIEW AND QUALITY
RESEARCH ENVIRONMENT
As reflected in Figures 1–3, the Baltic States have devel-
oped the legal and institutional structure for the ethical
review of human research. However, the fact that a
basic legal and institutional structure exists, does not
automatically guarantee high quality ethical review.
Although there can be no guarantees, there could be
more confidence in a review process that at a minimum
required: transparency in reporting REC activities and
findings; clear, precise and justifiable rules and prin-
ciples governing committee processes; specification of
the composition and required qualifications for commit-
tee members, requirements for reporting of research
process and findings; reliable funding and facilities
for the committee; and legal protection of intellectual
property. In this section we will briefly address several
problematic areas connected to the quality of ethical
review. These include: (a) availability of information,
(b) management of conflicts of interest, (c) committee
9 European Commission, op. cit. note 1.
Table 1. Workload of RECs in the Baltic States (excluding student research)
Lithuania Latvia Estonia
Population (millions) 3.56 2.23 1.34
Year 2007 2008 2007 2008 2007 2008
Clinical drug trials Number of approvals 112 108 85 88 93 103
Number of committees 1 1 4 4 2 2
Other human research Number of approvals 111 119 N/A N/A 114 127
Number of committees 2 2 6 6 2 2
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composition and motivation of REC members, and (d)
differing stringency of ethical review for different types
of studies.
Availability of information
Very few RECs in the region have websites that provide
information about their procedures of functioning.
Information on statutes, de facto composition, basic sta-
tistics on the number of reviewed research protocols (not
including the list of approved and rejected research
projects), in many cases, is not publicly available.10
Sometimes this information is not available even if rel-
evant institutions are contacted directly. The limited
10 An exception is the website of the Lithuanian Bioethics Committee
(Available at: http://bioetika.sam.lt [Accessed 31 Mar 2010]). This insti-
tution also has an official template for information requests and is
obliged to answer inquiries. However, even here information sometimes
is not regularly updated. For example, at the time of this research,
statistics on the number of reviewed protocols had not been updated
since mid-2005.
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availability of information adds to low public and pro-
fessional awareness of RECs.
In general, there is growing international support for
the dissemination of information on clinical trials via
publicly available clinical trial registries and databases.11
However, publicly accessible registries and databases are
typically lacking in smaller countries. In their absence,
RECs might become vehicles for improving the publicity
and transparency of biomedical research by providing
information on approved research projects on their own
websites.12
Conflicts of interest
The management of conflicts of interest has received only
limited attention in laws and regulations. The Baltic
systems of ethical review of human research rely solely on
voluntarily disclosure of potential conflicts of interest.13
This is not very troubling by itself – voluntarily disclosure
is a rather widespread model of managing conflicts of
interest in a number of different countries. However,
most of the RECs in the Baltic States are units within
universities or medical schools, and many or even most of
their members are representatives of the same institution
that conducts research projects. In addition, biomedical
communities are rather small and compact and subject to
subtle peer pressure. Therefore it is very difficult to deter-
mine the extent to which decisions of RECs are made
independently of the interests of researchers and spon-
sors, how often conflicts of interest occur, how serious
they are, and how are they avoided in practice. Open for
discussion is whether RECs that are affiliated with
research institutions and draw most of their members
from that institution (similar to IRBs in the USA) can
avoid conflicts of interest.
Another potential problem is that funding of RECs in
Estonia and Latvia is directly dependent on the number
of reviewed protocols.14 The Lithuanian system follows a
redistributive model, where the fees are first paid to the
budget of a third party (i.e. the state), from which the
committees are financed. Arguably, the former system
may be less likely to issue negative decisions, especially
in cases where researchers are free to choose the REC. In
Lithuania and Estonia, if approval is denied by a REC it
is not possible to seek approval for the same protocol
from another REC. For example, Estonian RECs, on a
quarterly basis, exchange lists of applications to help
eliminate ‘shopping for RECs’. However, in Latvia,
where different RECs are not assigned defined geo-
graphical regions, there is no system to exchange infor-
mation on refused applications. Therefore a protocol
refused by one REC can, at least in theory, be submitted
to another.
Committee composition and motivation of
REC members
RECs in the Baltic States usually include 7 to 15
members, most of whom have medical qualifications and
affiliations. Selection and composition criteria vary sig-
nificantly among committees in regard to their specificity
in defining the qualifications of individual members and
in the requirements for representation from various
bodies and organizations. For example, although compo-
sition criteria for Lithuanian regional RECs are defined
in detail by special ministerial decree,15 most committees
rely on general principles. For example, the only require-
ment for the composition of the subcommittee for ethical
review of biomedical research of the Lithuanian Bioethics
11 An example of one such database is ClinicalTrials.gov, a service of
the US National Institutes of Health (Available at: http://clinicaltrials.
gov [Accessed 31 Mar 2010]).
Also, Article 19 of Helsinki Declaration (World Medical Association.
Declaration of Helsinki – Ethical Principles for Medical Research Involv-
ing Human Subjects (Helsinki: 1964; amended Tokyo: 1975; Venice:
1983; Hong Kong: 1989; Republic of South Africa: 1996; Edinburgh:
2000; Washington: 2002; Tokyo 2004; Seoul 2008). Available at: http://
www.wma.net/en/30publications/10policies/b3/index.html [Accessed 31
Mar 2010].) states that: ‘Every clinical trial must be registered in a
publicly accessible database before recruitment of the first subject.’ This
idea was also supported by the International Committee of Editors of
Medical Journals which stipulates that member journals require authors
to register their trials (including methodology) in a registry that is
accessible to the public free of charge (International Committee
of Medical Journal Editors. 2009. Obligation to Register Clinical
Trials. Available at: http://www.icmje.org/publishing_10register.html
[Accessed 31 Mar 2010].). The European Commission also issued guide-
lines on the list of fields contained in the EudraCT clinical trials data-
base that should be made publicly available (European Commission.
2009. List of fields contained in the ‘EudraCT’ clinical trials database to
be made public, in accordance with Article 57(2) of Regulation (EC) No
726/2004 and its implementing guideline 2008/C168/02. Available at:
http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-10/2009_
02_04_guideline.pdf [Accessed 31 Mar 2010].).
12 The Ethics Review Committee on Human Research of the University
of Tartu has published an annual list of all approvals since 2008; see
Tartu Ülikooli inimuuringute eetika komitee (Ethics Review Committee
on Human Research of the University of Tartu). 2009. Tartu Ülikooli
inimuuringute eetika komitee menetlus 2008 (Approvals given by the
Ethics Review Committee on Human Research of the University of Tartu
in 2008). Available at: http://www.ut.ee/orb.aw/class=file/action=
preview/id=595718/Ec_2008_kokkuv6te.pdf [Accessed 31 Mar 2010].
13 For example, the Statutes of Tallinn MREC [provided by the REC]
simply state that members who are not ‘independent from the perform-
ers of the research’ may not vote.
14 In Latvia, it is true only of those RECs that review clinical drug trials.
15 Lietuvos Respublikos Sveikatos apsaugos ministerija (Ministry of
Health of the Republic of Lithuania). 2008. Lietuvos Respublikos sveika-
tos apsaugos ministro įsakymas dėl regioninių biomedicininių tyrimų
etikos komitetų narių skyrimo tvarkos aprašo patvirtinimo (Decree of
the Minister of Health of the Republic of Lithuania on the Procedure of
Nomination of the Members of Regional Biomedical Research Ethics
Committees). Valstybės žinios, 2008-06-17, Nr. 69-2635. Available
at: http://www3.lrs.lt/pls/inter3/dokpaieska.showdoc_l?p_id=322379
&p_query=&p_tr2= [Accessed 31 Mar 2010].
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Committee is to keep the balance between biomedical
and non-biomedical representation.16 Also, although the
membership of the Latvian Central Medical Ethics Com-
mittee must represent 11 organizations (Ministry of
Health, Council of Science, University of Latvia Institute
for Experimental and Clinical Medicine, Latvian Nurses
Association, Latvian Pensioners Federation, etc.),17 the
rationale for their membership is not clear. Furthermore,
except for being delegated by one of these organizations,
no formal individual qualifications are defined. In most
cases, however, criteria are stated relatively vaguely. For
example, the statutes of Ethics Review Committee on
Human Research of the University of Tartu state that it
should be composed of,
persons representing various different fields of life with
the preparation in the specialties of biomedicine as well
as in other specialties. Each member of the Ethics
Review Committee shall be a recognized specialist in
his or her field with the necessary expertise to perform
the duties of a member of the Ethics Review Commit-
tee and shall have an impeccable reputation.18
The definition of ‘necessary expertise’ is not further
specified.
The RECs themselves have identified the problem of
insufficient motivation of members. Reading the proto-
cols and attending meetings is time consuming and
usually members are not adequately paid for the work,
causing difficulty in recruiting highly qualified pro-
fessionals.19 The lack of financial incentives is not
outweighed by other types of motivation, such as pro-
fessional development, prestige or social status. For
example, there are no systematic training programs for
the members in the Baltic States. Most of the education
is acquired through practical work on the committee.
Some members participate in conferences or workshops,
but this is not done in any systematic or coordinated
way. Lack of respect by academic researchers for the
requirement of ethical review can also prevent qualified
scientists from working on RECs. Many perceive the
process as slowing down and hindering scientific
research. In general, the lack of motivators can result
in both poorer quality of ethical reviews and a reduc-
tion in the number of interested potential committee
candidates.20
Ethical review by types of human research
Procedural clarity and the scope of ethical review may
differ for different types of human research. Some types of
human research may even escape ethical review alto-
gether. Although, as previously mentioned, clinical drug
trials enjoy special status in all three countries, due to the
provisions of Directive 2001/20/EC,21 the situation is less
uniform in other cases. It is only in Lithuania where a legal
definition of biomedical research, and the requirement to
subject such research to review by REC, exists. The Law
on Ethics of Biomedical Research defines biomedical
research as ‘verification of hypotheses of biomedicine by
methods of scientific investigation and development of
knowledge about characteristics of human health’.22 This
broad definition includes research ‘carried out in individu-
als or their groups, a foetus, tissues, organs, cells and
genetic material, cadavers and medical documents’.23
Neither Latvian nor Estonian national law includes a
definition of biomedical research or clarifies why, in prac-
tice, some kinds of research involving human subjects
require ethical review by RECs and others do not. Some-
times specifications can be found in the statutes of particu-
lar RECs established at academic institutions, but
sanctions for non-compliance with these regulations are
limited to the jurisdiction of that institution. For example,
it seems that no sanctions could be applied to researchers
who are affiliated with institutions that do not have a REC
(e.g. any Estonian research institution except the Univer-
sity of Tartu and the National Institute for Health Devel-
opment) for failing to seek ethical review.2416 Lietuvos bioetikos komitetas (Lithuanian Bioethics Committee).
2007. Lietuvos bioetikos komiteto pirmininko įsakymas V-8 Dėl Lietu-
vos bioetikos komiteto biomedicininių tyrimų ekspertų grupės darbo
reglamento patvirtinimo (Decree of the Lithuanian Bioethics Committee
no. V-8 on the Working Procedures of the Biomedical Research Experts’
Group). Valstybės žinios, 2008-02-28, Nr. 24-893. Available at: http://
www3.lrs.lt/pls/inter3/dokpaieska.showdoc_l?p_id=315164&p_query=
&p_tr2= [Accessed 31 Mar 2010].
17 Latvijas Republikas Ministru kabinets (Cabinet of Ministers of the
Republic of Latvia), op. cit. note 7. Art. 3.
18 University of Tartu. 2007. Statute of the Ethics Review Committee
on Human Research of the University of Tartu. Available at: http://
www.ut.ee/orb.aw/class=file/action=preview/id=276573/
TY+Inimuuringute_et-en_070828_9015_statuut_en_ok-ED.pdf
[Accessed 31 Mar 2010].
19 For a general argument that REC members should be adequately
remunerated, see Ch. Druml et al. Research Ethics Committees
in Europe: Trials and Tribulations. Intensive Care Med 2009; 35:
1636–1640.
20 This also leads to the issue of rotation of REC members. Lack of
potential candidates may be dealt with by having no formal term limits
for an REC member. For example, in Estonia, term limits were intro-
duced only in 2007.
21 European Commission, op. cit. note 1.
22 Seimas of the Republic of Lithuania, op. cit. note 5, Art 2.1.
23 Ibid: Art 3.1.
24 For Estonia, some guidance can be found in the Oviedo Convention
(Council of Europe. 1997. Convention for the Protection of Human
Rights and Dignity of the Human Being with regard to the Application
of Biology and Medicine: Convention on Human Rights and Biomedi-
cine. Available at: http://conventions.coe.int/Treaty/en/Treaties/Html/
164.htm [Accessed 31 Mar 2010].). This treaty has been ratified
by Estonia and Lithuania but not Latvia. The Convention states
that human scientific research in the field of biology and biomedicine
cannot be conducted without ‘multidisciplinary review of its ethical
acceptability’ (Art 16.3).
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At the moment, according to law in the Baltic States,
non-biomedical human studies do not fall within the
scope of REC approval. Ethical review is not required for
conducting sociological, anthropological or psychologi-
cal research outside of healthcare context. When there are
no legally binding requirements, ethical review may be
enforced by what might be called ‘softer’ social regula-
tions, such as policies of RECs established at the univer-
sities or research institutes, requirements for authors
wishing to publish in scientific journals and guidelines
promulgated by different funding bodies sponsoring
human research. At least in one case, provisions to cover
non-biomedical human research are included in REC
policies. According to the statutes of Ethics Review Com-
mittee on Human Research of the University of Tartu,
the REC shall also assess the ethical aspects of human
research if a danger to the physical or mental health of
human(s) may occur while conducting the aforemen-
tioned research.25
Despite differences in REC systems and existing prac-
tices, we suggest that closer networking and cooperation
of RECs in the Baltic region would help to reduce prob-
lems related to the quality of the research environment
and open up possibilities for the advancement of research
ethics both on the regional and national levels, including
the development of common guidelines for ethical review
and the joint training of REC members. Baltic RECs
have already experienced positive results of such net-
working over the past few years.26
CONCLUDING REMARKS
The experience of the Baltic States, as transition societies,
may well be relevant to other transition societies. Over
the past two decades, the ethical review of human
research in the Baltic States has undergone significant
legal and institutional development, with each country
evolving in a separate direction. In many ways, the result-
ing systems adhere to international standards. However,
problems remain. For example, the limited transparency
and procedural clarity of ethical review hinder the cre-
ation of a quality research environment. RECs should be
encouraged to increase the availability of data on
reviewed protocols on their websites. New methods to
manage conflicts of interest need to be created taking into
account the influence that the structure of RECs has on
those conflicts. More effort should be made to establish
the optimal REC model in terms of composition of com-
mittees and motivation of their members. The legal envi-
ronment should also be improved. Networking among
RECs could be a potent tool to encourage the above-
mentioned processes.
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25 Human research conducted by students in educational setting may
also involve significant risks to research subjects and therefore should
receive ethical scrutiny. However, it may be impracticable to apply
stringent procedures to student research. There is no definition of
student research in Lithuanian, Latvian or Estonian legislation. Most
medical schools in the Baltic States have internal regulations concerning
the need for ethical review of student research. These internal regula-
tions are based on local initiative not on overarching national policies.
26 Information on the Baltic research ethics network activities can be
found on the website of Lithuanian Bioethics Committee. Available at:
http://bioetika.sam.lt/index.php?-809972162 [Accessed 31 Mar 2010]).
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